These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34908192)

  • 1. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation.
    Ständer S; Zeidler C; Pereira M; Szepietowski JC; McLeod L; Qin S; Williams N; Sciascia T; Augustin M
    J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):573-581. PubMed ID: 34908192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
    Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
    JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials.
    Kwatra SG; Yosipovitch G; Kim B; Stander S; Rhoten S; Ivanescu C; Haeusler N; Brookes E; Msihid J; Makhija M; Bansal A; Thomas RB; Bahloul D
    JAMA Dermatol; 2024 Aug; 160(8):813-821. PubMed ID: 38865146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
    Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
    Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
    Vernon MK; Swett LL; Speck RM; Munera C; Spencer RH; Wen W; Menzaghi F
    J Patient Rep Outcomes; 2021 Dec; 5(1):134. PubMed ID: 34952964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
    Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J
    Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
    Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
    EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population pharmacokinetic-pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis.
    Eudy-Byrne R; Riggs M; Hawi A; Sciascia T; Rohatagi S
    Br J Clin Pharmacol; 2023 Jul; 89(7):2088-2101. PubMed ID: 36680419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase.
    Weisshaar E; Szepietowski JC; Bernhard JD; Hait H; Legat FJ; Nattkemper L; Reich A; Sadoghi B; Sciascia TR; Zeidler C; Yosipovitch G; Ständer S
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):453-461. PubMed ID: 34780095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.
    Kimball AB; Naegeli AN; Edson-Heredia E; Lin CY; Gaich C; Nikaï E; Wyrwich K; Yosipovitch G
    Br J Dermatol; 2016 Jul; 175(1):157-62. PubMed ID: 26852717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
    Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.
    Kwatra SG; Yosipovitch G; Ständer S; Guillemin I; Msihid J; Bansal A; Makhija M; Wiggins S; Zahn J; Thomas RB; Bahloul D
    J Eur Acad Dermatol Venereol; 2024 Oct; 38(10):1965-1972. PubMed ID: 38785405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
    Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.
    Yokozeki H; Murota H; Matsumura T; Komazaki H;
    Br J Dermatol; 2024 Jul; 191(2):200-208. PubMed ID: 38629497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
    Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
    Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
    Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT
    Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial.
    Kwatra SG; Bordeaux ZA; Parthasarathy V; Kollhoff AL; Alajmi A; Pritchard T; Cornman HL; Kambala A; Lee KK; Manjunath J; Ma EZ; Dillen C; Kwatra MM
    JAMA Dermatol; 2024 Jul; 160(7):717-724. PubMed ID: 38837144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
    Rams A; Baldasaro J; Bunod L; Delbecque L; Strzok S; Meunier J; ElMaraghy H; Sun L; Pierce E
    Adv Ther; 2024 Apr; 41(4):1512-1525. PubMed ID: 38363461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
    Husein-ElAhmed H; Steinhoff M
    J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.